Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

First infant MRI study finds babies feel pain ‘like adults’

(Reuters) – The brains of babies “light up” in a similar way to adults when exposed to the same painful stimulus, suggesting they feel pain much like adults do, researchers said on Tuesday. In the first of its kind study using magnetic resonance imaging (MRI), scientists from Britain’s Oxford University found that 18 of the […]

Read More »

Sexual dysfunction may accompany PTSD

(Reuters Health) – Men and women with post-traumatic stress disorder (PTSD) may also experience sexual dysfunction and relationship difficulties, a new research review suggests. “Persons with PTSD often complain of sexual dysfunction and problems with intimacy more generally,” and there’s increasing evidence to support this association, said lead study author Rachel Yehuda in an email. […]

Read More »

Protein identified that serves as a “break” on inflammation

MEMPHIS, Tenn., April 21, 2015 /PRNewswire-USNewswire/ — Researchers have identified a protein that offers a new focus for developing targeted therapies to tame the severe inflammation associated with multiple sclerosis (MS), colitis and other autoimmune disorders. St. Jude Children’s Research Hospital scientists led the study which appears today in the scientific journal Immunity. Investigators showed that […]

Read More »

In Historic First, San Francisco Board of Supervisors Votes to Take Tobacco Out of Baseball

SAN FRANCISCO, April 21, 2015 /PRNewswire-USNewswire/ — Today the San Francisco Board of Supervisors unanimously passed an ordinance to prohibit use of all tobacco products – including smokeless tobacco – at all baseball venues and athletic fields within the city and county of San Francisco, including by fans and players at AT&T Park. San Francisco […]

Read More »

Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics

TOKYO and CAMBRIDGE, Mass., April 21, 2015 /PRNewswire/ — Astellas Pharma Inc. (Tokyo: 4503) and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration.  The goal of the collaboration is to advance a portfolio consisting of programs with novel mechanisms of action targeting immune checkpoint […]

Read More »

Cantrixil Receives Orphan Drug Designation from FDA

SYDNEY, April 21, 2015 /PRNewswire/ — US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer. Orphan Drug Designation is an important […]

Read More »

Belgium, Netherlands plan joint purchase of rare disease drugs

(Reuters) – Belgium and the Netherlands will jointly negotiate the purchase of remedies for rare diseases with pharmaceutical groups, the Belgian health ministry said on Tuesday. The joint negotiations will focus on diseases which affect fewer than five in 100,000 people, so-called orphan diseases, for which treatments are often very expensive due to the limited […]

Read More »

Israel’s BrainStorm says stem cell drug benefits ALS patients

(Reuters) – Israel’s BrainStorm Cell Therapeutics said a mid-stage clinical trial of its adult stem cell treatment showed a “statistically significant” effect in patients with amyotrophic lateral sclerosis (ALS). According to the ALS Association, 5,600 people in the United States are diagnosed each year with the neurodegenerative disease, also known as Lou Gehrig’s Disease, which […]

Read More »

Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. announced today that XALKORI® (crizotinib) received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC). Occurring in approximately one percent of NSCLC cases1, ROS1-positive NSCLC represents a particular molecular subgroup of NSCLC.2 XALKORI currently is approved […]

Read More »

AstraZeneca drug Lynparza shows promise in prostate cancer trial

(Reuters) – AstraZeneca’s recently approved ovarian cancer drug Lynparza, or olaparib, can also help men with prostate cancer, according to new clinical trial results on Tuesday. The news is the latest boost to the British company’s cancer drug pipeline, which formed a central plank of its defense against a $118 billion takeover attempt by Pfizer […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom